Graham Capital Management L.P. Grows Stock Holdings in Esperion Therapeutics, Inc. $ESPR

Key Points

• Graham Capital Management L.P. increased its stake in Esperion Therapeutics, Inc. by 153.5%, acquiring an additional 295,320 shares, bringing its total holdings to 487,735 shares worth approximately $702,000.
• Several institutional investors, including Nuveen LLC and Bank of America Corp DE, also reported significant increases in their positions in Esperion, highlighting growing interest in the company.
• Esperion's stock currently has a market capitalization of $510.10 million and recently reported quarterly earnings that exceeded analysts' expectations, indicating a potential turnaround in its financial performance.

Graham Capital Management L.P. raised its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 153.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 487,735 shares of the biopharmaceutical company's stock after purchasing an additional 295,320 shares during the period. Graham Capital Management L.P. owned about 0.25% of Esperion Therapeutics worth $702,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ESPR. Meridian Wealth Management LLC acquired a new position in shares of Esperion Therapeutics in the first quarter valued at approximately $29,000. Synergy Asset Management LLC grew its stake in Esperion Therapeutics by 3,496.3% in the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 30,138 shares during the period. Private Advisor Group LLC raised its holdings in Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock valued at $58,000 after acquiring an additional 10,000 shares during the last quarter. Crestline Management LP acquired a new position in Esperion Therapeutics in the 4th quarter valued at $63,000. Finally, SLT Holdings LLC lifted its stake in shares of Esperion Therapeutics by 66.7% during the 1st quarter. SLT Holdings LLC now owns 50,000 shares of the biopharmaceutical company's stock worth $72,000 after purchasing an additional 20,000 shares during the period. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Stock Up 2.4%

Shares of ESPR stock traded up $0.06 on Wednesday, reaching $2.60. 5,872,218 shares of the stock were exchanged, compared to its average volume of 6,026,057. The stock has a market cap of $524.21 million, a P/E ratio of -5.31, a price-to-earnings-growth ratio of 57.05 and a beta of 0.89. The firm has a 50 day moving average of $1.76 and a two-hundred day moving average of $1.37. Esperion Therapeutics, Inc. has a 1-year low of $0.69 and a 1-year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.15. The firm had revenue of $82.39 million during the quarter, compared to the consensus estimate of $62.55 million. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%. On average, equities research analysts predict that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Wall Street Zen downgraded Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, August 25th. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.